As of Feb 27
| -0.65 / -2.09%|
The 11 analysts offering 12-month price forecasts for Genomic Health Inc have a median target of 31.00, with a high estimate of 40.00 and a low estimate of 20.00. The median estimate represents a +1.97% increase from the last price of 30.40.
The current consensus among 15 polled investment analysts is to Hold stock in Genomic Health Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.